ATROSIMAB

Indicaton

inflammatory diseases (rheumatoid arthritis, Morbus Crohn), CNS diseases (Multiple Sclerosis, Alzheimer, Spinal Cord Injury), cardiovascular diseases (Myocardial infarction, TBI) and NASH

Therapeutic indications

Type of product

Antibody

Table

Phase

Phase I completed
Partnering status

Not partnered
Available in

Worldwide

You may also be interested in

Dipraglurant (mGlu5 NAM) for PD-LID

Milestone: Indication under evaluation Dipraglurant is a novel orally available highly selective metabotropic glutamate receptor subtype 5 negative allosteric modulator (mGlu5 NAM) which has completed Phase 1 and demonstrated efficacy in a Phase 2a proof of concept study for the treatment of levodopa-induced dyskinesia associated with Parkinson’s disease (PD-LID).

Phase II started

AUP-16 (AUP1602-C)

AUP-16 is a multi-therapy live bacterial vector for chronic wounds: Diabetic Foot, Leg & Pressure Ulcers